,
García-Escobar, I. http://orcid.org/0000-0002-1068-0455
Brozos-Vázquez, E.
Gutierrez Abad, D.
Martínez-Marín, V.
Pachón, V.
Muñoz Martín, A. J.
Funding for this research was provided by:
Spanish Society of Medical Oncology (SEOM).
Article History
Received: 8 May 2020
Accepted: 28 September 2020
First Online: 18 November 2020
Compliance with ethical standards
:
: IG-E has been an advisory board member for Leo Pharma and has received speaker honoraria from Leo Pharma. EB-V has received speaker honoraria from Leo Pharma and Rovi. VP has been an advisory board member for DAICHI and has received speaker honoraria from Sanofi and Leo Pharma. AJMM declares the following conflicts of interest: Advisory boards: Celgene, Astra-Zeneca, Roche, Servier, Sanofi, Pfizer, Bristol-Myers Squibb, Leo Pharma, Daiichi Sankyo, Bayer and Halozyme; Speaker’s bureau: Rovi, Lilly, Merck Sharp & Dohme; Research funding: Sanofi and Leo Pharma; Travel, Accommodations, Expenses: Celgene, Roche, Merck Serono, Amgen, Sanofi; Patents, royalties, other intellectual property: Risk assessment model in venous thromboembolism in patients with cancer. DGA and VM-M declare no conflicts of interest.
: The manuscript does not contain any studies with human participants or animals performed by any of the authors.
: Informed consent/ethical approval was not required.